Advanced neuroimaging intelligence for precision medicine.

Population-referenced brain imaging biomarkers compare an individual brain scan against large-scale reference data spanning the human lifespan to flag meaningful deviations tied to development, aging, or disease, rather than assessing a single scan in isolation the way a standard radiological read does. Centile Bio builds these quantitative reference models using more than a million imaging studies from over 200,000 individuals, creating gold-standard benchmarks for conditions like autism, dementia, and traumatic brain injury.

Quantitative neuroimaging biomarkers can serve as objective trial endpoints, supporting patient stratification and tracking therapeutic response over time with more precision and consistency than standard radiological review alone. The platform built by Centile Bio provides research-grade, population-referenced outputs designed specifically for translational use in CNS drug development, giving pharma and biotech teams a measurable signal to anchor discovery and clinical translation decisions.

No. Quantitative neuroimaging platforms are generally designed to integrate into existing imaging workflows using standard acquisition protocols, avoiding the cost and disruption of new hardware. CentileOS, the platform from Centile Bio, is built to be compatible with any standard MRI or CT scanner across vendors and clinical sites, quantifying studies across different protocols, sequences, and formats without requiring a new acquisition process.

HIPAA-compliant neuroimaging platforms typically support a proprietary de-identification pipeline and offer flexible deployment models, including on-premise options, so protected health information never has to leave a secure, high-sensitivity data environment unnecessarily. Centile Bio's infrastructure is built specifically for PHI-safe workflows, supporting both identified and de-identified data depending on the compliance requirements of the health system, clinic, or research partner.

Quantitative brain reference models are used to track development and disease processes including autism, dementia, normal pressure hydrocephalus, and traumatic brain injury, by measuring how an individual's scan deviates from age-adjusted population norms over time rather than relying on a single static read. Centile Bio's technology, including its TBI-REPORTER grant-funded work and ongoing brain charting research, has been applied to each of these areas, with validation published in leading peer-reviewed radiology journals.

Archived imaging studies often sit unused in a hospital's data infrastructure after the original clinical read, but running them through a quantification layer can surface longitudinal, population-referenced insight that wasn't accessible through the initial scan review. Centile Bio's CentileOS platform is designed to activate exactly this kind of idle imaging archive for health systems, turning what was a static clinical record into a measurable, reusable asset for research, diagnostics, and long-term patient monitoring.